Sarah Urbut: Predicting Your Health Arc - Ground Truths | Eric Topol

National Day of Truth and Reconciliation at Rady commemorated difficult events, highlighted reconciliation initiatives and included the first community walk at the Bannatyne campus. Rady faculty, staff and learners participate in first Orange Shirt Day Community Walk on Bannatyne Campus.

Infection with the human papillomavirus (HPV) is extremely common and, in the vast majority of cases, clears up on its own. However, in some people, the infection persists and can develop into precancerous lesions or even cancer. How can these high-risk situations be identified at an early stage? This is the central question of a study conducted by Michael Herfs’s team at the Interdisciplinary Biomedical Research Center GIGA’s Laboratory of Experimental Pathology at the University of Liège, published in Trends in Molecular Medicine. For several decades, researchers have sought to identify biomarkers capable of accurately predicting the outcome of an infection with a high-risk oncogenic HPV type. Despite significant advances, no viral, immune-related, or molecular marker can currently and reliably predict which infections will regress spontaneously and which will progress to more severe disease.

Bioengineer.org news storyFor people living with HIV, modern antiretroviral therapy can suppress the virus to levels below what standard laboratory tests can detect. Yet some patients on long-term treatment experience a curious phenomenon: a single test result showing a small, transient amount of virus in the blood, followed by an immediate return to undetectable levels. These events, known as viral blips, have puzzled clinicians and researchers for years, raising questions about whether they represent harmless statistical noise, brief bursts of viral production from hidden reservoirs, or early warnings of impending treatment failure. A new nationwide Swedish study, published in BMC Infectious Diseases, offers one of the most comprehensive answers to date. Drawing on the Swedish national InfCareHIV cohort, researchers analyzed data from 4,210 treatment-naïve adults who began antiretroviral therapy from 1 January 2007 onward, with follow-up data extracted through 30 September 2020. The median observation time was 5.5 years, with some individuals followed for as long as 13.7 years.